Condition
Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
3 treatments under study, led by Quadruple Therapy
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Not Applicable (1)
Trial Status
Recruiting1
Unknown1
Clinical Trials (2)
Research Network
Common Treatments
- Quadruple Therapy1
- Triple Therapy1
- Dualpriming Oligonucleotidebased Multiplex Dpopcr Test1
Active Sponsors
- Seoul National University Bundang Hospital1
- Seoul National University Hospital1
Top Investigators
Department of Internal Medicine and Liver Research Institute,
Seoul National University Bundang Hospital
Related Conditions
- Helicobacter Pylori Infection2
- Helicobacter Pylori Associated Gastrointestinal Disease1
- Helicobacter Pylori Infection Susceptibility To1